Related Experiment Video
Updated: Feb 13, 2026

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023
Cefepime Efficacy and Safety in Children: A Systematic Review and Meta-analysis
Saber Jan1,2, Braveen Ragunanthan3, Sandra R DiBrito4
1Division of Pediatric Neurology, Department of Pediatrics The Hospital for Sick Children, Toronto, ON, Canada.
Insights
Cefepime (a fourth-generation cephalosporin) showed no significant difference in efficacy or mortality compared to other antibiotics in children. Further research is needed due to study limitations and unclear safety data in pediatric patients.
Area of Science:
- Pediatric Infectious Diseases
- Antibiotic Efficacy and Safety
- Pharmacology
Background:
- Cefepime, a fourth-generation cephalosporin, is approved for pediatric infections.
- Existing data on cefepime's efficacy and safety in children are inconsistent.
- This review addresses the need for clarity on cefepime use in pediatric populations.
Purpose of the Study:
- To compare the efficacy and all-cause mortality of cefepime versus other antibiotics in pediatric patients.
- To evaluate secondary outcomes including treatment success, failure, and adverse events.
- To synthesize current evidence on cefepime's clinical utility in children.
Main Methods:
- Systematic search of multiple databases (MEDLINE, EMBASE, CENTRAL, LILACS, clinicaltrials.gov) up to February 2016.
- Inclusion of randomized controlled trials (RCTs) in pediatric patients (0-19 years) with infections.
- Primary outcome: all-cause mortality; Secondary outcomes: success rate, treatment failure, adverse events. Assessed study quality using Cochrane Risk of Bias.
Main Results:
- Seventeen studies with 1,285 participants (624 cefepime, 661 comparator) were included.
- Meta-analysis revealed no significant difference in all-cause mortality (RR 0.88; 95% CI: 0.71-1.08).
- No significant differences observed in success rates (RR 0.98; 95% CI: 0.92-1.05) or treatment failure (RR 1.04; 95% CI: 0.91-1.19). Adverse events were not statistically assessed due to heterogeneity.
Conclusions:
- The efficacy and safety of cefepime in pediatric patients remain uncertain.
- High heterogeneity and methodological flaws limit the current evidence base.
- Despite recent trials, a decade after the last review, clarity on cefepime's role in pediatric care is still lacking.
Background:
Cefepime is a fourth-generation cephalosporin antibiotic used to treat a variety of infections. The US Food and Drug Administration approved its use in certain types of infections among pediatric patients, and yet there have been mixed data about its efficacy and safety in this population.
Objective:
The objective of this review is to compare efficacy and all-cause mortality of cefepime to other clinically indicated antibiotics among children.
Methods:
We conducted a systematic search of MEDLINE, EMBASE, CENTRAL, LILACS, and clinicaltrials.gov databases through February 8, 2016. We included randomized controlled trials comparing cefepime to other clinical antibiotics, placebo, or no treatment in children aged 0-19 years in the inpatient setting with clinical signs of infection. The primary outcome of interest was all-cause mortality. The secondary outcomes were success rate, treatment failure, and incidence of adverse events. Study quality was assessed using the Cochrane Risk of Bias Assessment Tool.
Results:
Seventeen studies met the inclusion criteria. There was a total of 1,285 participants included, 624 participants in the cefepime arm and 661 in the comparison arm. A random effects meta-analysis for all-cause mortality showed no difference in rates of mortality between cefepime and comparator antibiotics with a mortality risk ratio of 0.88 (95% CI: 0.71-1.08). For the secondary outcomes of success rate and treatment failure, a random effects model meta-analysis conducted of the studies showed no difference in rate between cefepime and comparator antibiotics with an overall risk ratio of 0.98 (95% CI: 0.92-1.05) and 1.04 (95% CI: 0.91-1.19), respectively. Adverse events were not statistically assessed given widespread heterogeneity. Overall, the studies had unclear risk of bias and were limited by high heterogeneity and methodological flaws.
Conclusion:
The efficacy and safety of cefepime in pediatric patients remain unclear despite the inclusion of newer trials since the last index systematic review conducted a decade ago.
Related Concept Videos
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Survey Safety
Self-Efficacy
Random and Systematic Errors
Directing Effect of Substituents: meta-Directing Groups

